who harbored EGFR activating mutations and received erlotinib as first line treatment, were examined for EGFR amplification by FISH. We analyzed the relationship between EGFR mutational status and copy number profile with clinical outcomes including response rate, overallsurvival (OS), and PFS. Results: Median age was 62-years (range: 20-87 years), 53 patients were females (73%), and 68 (94.5%) had common mutations. Twenty-two (30.6%) samples with EGFR activating mutations were identified as having EGFR amplification. EGFR amplification was more frequent in patients with exon 19 deletion (p¼0.05) and in those with better performance status (p¼0.01). Patients with EGFR gene amplification had a significantly longer PFS than those without [(28.5 months, Background: Immunotherapies targeting the Programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) axis have showed favorable results in nonesmall cell lung cancer (NSCLC) patients. However, there is controversy regarding the analysis of PD-L1 expression by immunohistochemistry, particularly the cut-off criteria: Pembrolizumab with the 22C3 assay with cut-off ranges of >1%, 1-49% and >50%; and Nivolumab with the 28-8 assay and ranges of <1%, 1-5%, 5 -10% and >10%. Furthermore, the association between the histological subtype of adenocarcinoma and PD-L1 expression remains unclear. In this work, we assessed the frequency of PD-L1 expression according to the histological subtype of adenocarcinoma. Method: PD-L1 expression was evaluated using the PD-L1 IHC 22C3 pharmDx immunohistochemistry assay (Dako North America, Inc.). The histological subtype of adenocarcinoma was correlated with the frequency and intensity of PD-L1 expression, clinical variables, smoking history, EGFR and ALK status. Results: Tissue samples from one hundred and eighty-two patients were analyzed, 106 patients (57%) were female, the median age was 61 years (range 31-86 years), 53.7% were never-smokers with no exposition to wood smoke or asbestos (62.3 and 91% respectively). Regarding the histological subtypes, 32.1% were acinar, 25.3% solid, 15.4% papillar, 3.1% lepidic, 1.9% micropapillar; 52% had a moderated tumor differentiation grade. Fifty-six patients (43%) had EGFR mutations and eight patients (6.4%) had ALK rearrangements. Concerning to PD-L1 score, 42.9% of the patients were classified as negative (PD-L1<1%), 48.3% as lower (PD-L1 1 to 49%), and 8.8% as high (PD-L1>50%) expressors. A high PD-L1 tumor expression was associated solid histological subtype (p<0.05). Between patients with EGFR mutation or ALK rearrangements, 49% and
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